Get a glimpse into our company and investor data—powered by the PitchBook Platform
Developer of innovative wound healing technology intended to provide high-value therapeutics. The company's innovative wound healing technology uses CA5 HIF plasmid transfection with electroporation, enabling patients and health institutions to avail fast and effective cure to accelerate wound healing in acute and chronic wounds.
You’re viewing a free company profile from the PitchBook Platform. To explore Canton Biotechnologies’s full profile, request a free trial.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Grant | 01-Jan-2015 | $512K | 0000 | Completed | Generating Revenue | |
2. Early Stage VC | 17-Aug-2006 | 0000 | 0000 | Completed | Startup | |
1. Accelerator/Incubator | Completed | Startup |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
---|---|---|---|---|---|---|
National Institutes of Health | Government | 000 0000 | 000000 0 | |||
United States Department of Defense | Government | 000 0000 | 000000 0 | |||
U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | |||
TEDCO | Venture Capital | Minority | 000 0000 | 000000 0 | ||
Johns Hopkins Technology Ventures | Accelerator/Incubator | 000 0000 | 000000 0 |
Name | Title | Board Seat |
Contact Info |
---|---|---|---|
John Harmon | President |
1 Former Executive
You’re viewing 1 of 2 executives. Get the full list »